[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Venture Life Group Plc LSE:VLG London Ordinary Share GB00BFPM8908 ORD 0.3P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.60 4.11% 65.80 65.60 66.00 65.80 63.20 63.20 222,489 16:25:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 30.1 3.3 2.7 24.0 83

Venture Life Share Discussion Threads

Showing 35726 to 35750 of 36000 messages
Chat Pages: 1440  1439  1438  1437  1436  1435  1434  1433  1432  1431  1430  1429  Older
DateSubjectAuthorDiscuss
08/2/2021
18:40
Got to say that this one is on a yellow card for me. I'll give it until the end March.
mallorca 9
04/2/2021
08:32
Unthinking sheep. Something fishy. Smelling a rat. And now a BOD of snakes. Just need rain for 40 days and 40 nights now. edit - plenty of less than salutary comments on Stocko today. They need to have a PR rethink.
farnesbarnes
02/2/2021
15:35
Good to see that VLG have signed up with InvestorMeetCompany. Hopefully, we will get the opportunity to put questions direct to management before too long.
effortless cool
02/2/2021
12:01
The Cenkos note from November maps out why Slater went from 5% to 15%. It's all quite clear and if management deliver on this then there is 50% to 100% upside over the next 12 to 18 months. In a Covid variant world this is an excellent risk reward play.
simon gordon
02/2/2021
11:52
I like the growth story so bought some more this morning... And if an acquisition (or more than one) was to happen that took EBITDA to £10m -£12m or above then it looks very cheap to me.
thedudie
02/2/2021
11:10
Impressive list. Reassuring. If we have all got this wrong, then there will be a lot of very successful investment managers with egg on their face too. Unlikely to happen imo.
speedsgh
02/2/2021
10:45
The updated major shareholder list post-placing is worth a look - this represents almost 63% of the shares in issue. Quite a stellar list of holders, with Slater and BlackRock at the top: Shareholder Number of shares held % issued share capital Slater Investments 19,121,431 15.2% BlackRock 10,287,191 8.2% BGF Investment Management Limited 9,581,824 7.6% Hargreaves Lansdown 7,470,972 5.9% Directors 6,440,937 5.1% River & Mercantile Asset Management LLP 6,437,200 5.1% JO Hambro Capital Management 5,555,000 4.4% Close Brother Asset Management 5,538,410 4.4% Stonehage Fleming 5,093,438 4.0% Chelverton Asset Management 3,778,000 3.0%
rivaldo
02/2/2021
09:43
Shall wait for the acquisition announcements, until then I won't be investing here.
frankwhite
02/2/2021
08:46
Thank you rivaldo GLAH of which I am no longer one.
shanklin
02/2/2021
08:09
Thanks Riv, let's see if demand can get this back into the 90s at least AND the board can start delivering some +ve news flow to justify higher....GLA
qs99
01/2/2021
23:01
Here's Cenkos' investment update today for the record: "Venture Life Group has announced a trading update for the year to December 2020. The company expects revenues to be up 49% to £30.1m and adjusted EBITDA to be at least £6m, up over 100% YoY and indicating a margin of c20% over 500bps up on FY19A’s c15%. These results highlight an exceptional year for the company despite the pandemic. With a balance sheet strengthened to enable targeted acquisitions to build on the double-digit revenue growth we forecast for FY21E, we believe the year ahead should be another exceptional year for the company. We reiterate our Buy recommendation. FY20E – Venture Life expects to report FY20E revenues of £30.1m, up 49% YoY and in-line with our pre-update £30.3m forecast. Adjusted EBITDA is expected to be at least £6m, in line with our forecast £6.0m, which we have kept unchanged. Revenues – The company states that there were no further shipments of products to China in H2/20E, but that shipments will resume in H1/21E, as such we believe that a certain amount of revenues may have been deferred from FY20E into FY21E. This being the case, it would also indicate stronger than expected revenue generation from product sales outside of China and from third-party brand manufacturing. Acquisitions – Acquired at the start of 2020, Venture Life notes that PharmaSource revenues grew through the year despite the pandemic and they have achieved a number of synergies to date. We expect that following the recent fund raise, announced in Nov-20, further acquisitions will be completed through 2021E. Forecasts – We have updated our forecasts in-line with the FY20E trading update and given the minimal adjustments have kept our FY21E forecasts unchanged. For FY20E we lowered revenues by £0.2m and offset this at the gross profit line, given the larger proportion of higher margin Venture Brand revenues expected in FY20E. Investment thesis – Venture Life has delivered a strong growth year despite the COVID-19 pandemic. Including the PharmaSource acquisition completed in January, Venture Life has delivered 49% revenue growth and an adjusted EBITDA margin up c500bps on FY19A. With further acquisitions set to add to our forecast c11% organic revenue growth for FY21E, we expect another strong year ahead and see the current valuation offering an attractive opportunity. We reiterate our Buy recommendation."
rivaldo
01/2/2021
18:59
If you take off the cash of £35.5m from the market cap of £111m then divide by earnings for 2020 of £6m, you get a PE ratio of ~12.5 which is excellent for an AIM small cap company. Let's hope they use that £35.5m wisely to make an earnings enhancing acquisition with savings through synergies then we should all be happy. Meanwhile I'm using their Dentyl mouthwash every evening to kill off any of those Covid nasties that may have taken up residence throughout the day! 😉
bountyhunter
01/2/2021
17:35
"expected to be not less than £6m" - yes, that is what has put people's backs up - Cenkos forecast £6m back in November so 'not less than' that amount does not warrant the headline at the top picked out from everything else in colour (except the ADVFN version) proclaiming "Full year profit ahead of market expectations". On another board a poster complains of VLG's "rampy" RNSs.
sharw
01/2/2021
17:25
QS, is there an echo in here? I remember saying I smelt a rat about 6 weeks ago and was lambasted for it.
farnesbarnes
01/2/2021
16:59
Featured in today's Investor's Champion Bonkers Bargains update – Adjusted EBITDA (before the deduction of exceptional items and share based payments - expect plenty of these!) for the year ending 31 December is expected to be not less than £6m, more than double the 2019 adjusted EBITDA
energeticbacker
01/2/2021
16:02
Last one for me, but isn't VLG one of Simon T's (IC) favourites? So hopefully will get an update from him, +ve I hope! DYOR
qs99
01/2/2021
16:00
Hopefully that seller now gone
qs99
01/2/2021
14:55
thanks Shanklin, good analysis....always hard to see the share price fall like this, but still think the macro thesis is right on this one so am holding on! DYOR
qs99
01/2/2021
14:48
QS99 Re organic sales growth, sales in the last four half years in GBP are 9.39, 10.8, 16.9, 13.2 (oldest first). So: - growth in H1 YoY was 80%, mainly organic but 15% (i.e. £1.4m) due to the Jan-20 PharmaSource acquisition, per the H1 results. - growth in H2 YoY was 22%, presumably a fair bit due to PharamaSource albeit it is not broken down for us. If we assume Pharmasource also achieved £1.4m in H2, growth in the rest of the business was 1m on the previously H2's 10.8m, i.e just over 10%.
shanklin
01/2/2021
14:42
Discodave, on the contrary you make soime very valid points for which I am grateful for. I meant to top up my small holding last month but forgot which was a lucky escape. Mr Market agrees with you Dave and your sale has proved timely. I might try and call the bottom here despite the shenanigans.
mach100
01/2/2021
14:30
big volumes today, must be an insti getting out IMO....as you say, not the reaction management would have wanted, probs focused round the China shortfall, but they have then made expectations so underlying "other" organic growth must have been pretty good? DYOR
qs99
01/2/2021
14:29
Getting into real bargain territory now imo. Whether to top up now or later depends on your attitude as to whether to buy before or after acquisition and other news flow. My attitude is usually to buy before, but others will have different views.
rivaldo
01/2/2021
14:18
My stop loss at 80p has made the decision for me. Some not quite right here.
frankwhite
01/2/2021
14:10
really interesting....so do all the deals and proforma EBITDA could be c.£15-16m....that would put today's market cap into the shade IMO.....and with some debt on board they reckon more M&A is possible....so DYOR but c'mon VLG get on with it!!
qs99
01/2/2021
14:07
Simon, thanks will do.
qs99
Chat Pages: 1440  1439  1438  1437  1436  1435  1434  1433  1432  1431  1430  1429  Older
ADVFN Advertorial
Your Recent History
LSE
VLG
Venture Li..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210922 02:28:01